E. Shelley Hwang
- Cancer Research top 0.5%
- Breast Cancer Treatment Studies 58
- Cancer Genomics and Diagnostics 9
-
- Breast Lesions and Carcinomas 33
- Oncology top 2%
- Global Cancer Incidence and Screening 16
- Cancer Treatment and Pharmacology 7
- Surgery top 5%
- Breast Implant and Reconstruction 22
-
- BRCA gene mutations in cancer 7
-
- Health Systems, Economic Evaluations, Quality of Life 6
- Co-authors
- Rachel A. GreenupLaura J. EssermanSamantha M. ThomasJennifer K. PlichtaLisa A. CareyTerry HyslopLaura H. RosenbergerPatricia A. Spears
- Journals
- Journal of Clinical Oncology (4 papers)JNCI Journal of the National Cancer Institute (2 papers)Cancer (4 papers)
- Partner nations
- United StatesUnited KingdomNetherlands
In The Last Decade
E. Shelley Hwang
92 papers receiving 3.3k citations
Hit Papers
Peers
Comparison fields: 5 of 132
- Cancer Research 1.8k
- Pathology and Forensic Medicine 964
- Oncology 1.3k
- Radiology, Nuclear Medicine and Imaging 483
- Surgery 708
Countries citing papers authored by E. Shelley Hwang
This map shows the geographic impact of E. Shelley Hwang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Shelley Hwang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Shelley Hwang more than expected).
Fields of papers citing papers by E. Shelley Hwang
This network shows the impact of papers produced by E. Shelley Hwang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Shelley Hwang. The network helps show where E. Shelley Hwang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside E. Shelley Hwang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 1 | |
| 5 | 2022 | 0 | |
| 6 | 2021 | 11 | |
| 7 | 2021 | 10 | |
| 8 | Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guidelinebreakdown → | 2021 | 592 |
| 9 | 2020 | 11 | |
| 10 | 2020 | 6 | |
| 11 | 2020 | 35 | |
| 12 | 2019 | 13 | |
| 13 | 2019 | 21 | |
| 14 | 2018 | 12 | |
| 15 | 2018 | 90 | |
| 16 | 2017 | 15 | |
| 17 | 2016 | 17 | |
| 18 | 2013 | 152 | |
| 19 | 2010 | 25 | |
| 20 | 2000 | 20 |
About E. Shelley Hwang
E. Shelley Hwang is a scholar working on Cancer Research, Pathology and Forensic Medicine and Oncology, having authored 96 papers that have together received 3.3k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (58 papers), Breast Lesions and Carcinomas (33 papers), Breast Implant and Reconstruction (22 papers), Global Cancer Incidence and Screening (16 papers), Cancer Genomics and Diagnostics (9 papers), BRCA gene mutations in cancer (7 papers), Cancer Treatment and Pharmacology (7 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). The work is most often cited by research in Cancer Research (1.8k citations), Pathology and Forensic Medicine (964 citations) and Oncology (1.3k citations). E. Shelley Hwang has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Rachel A. Greenup, Laura J. Esserman, Samantha M. Thomas, Jennifer K. Plichta, Lisa A. Carey, Terry Hyslop, Laura H. Rosenberger, Patricia A. Spears, Mark R. Somerfield and Neelima Denduluri. Their work appears in journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.